Targeting Hedgehog signaling to improve treatment for ovarian cancer
Official title: Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence
Funded at Texas Tech University Health Scis Center · NIH-10545765 · Data updated 2026-11-12
This study is looking at how a specific pathway in ovarian cancer cells can be targeted to help make treatments work better for patients whose cancer keeps coming back after initial therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Tech University Health Scis Center NIH-funded |
| Lab location | 1 site (Lubbock, United States) |
| Project start | February 15, 2018 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $317,162 |
| NIH project number | 5R01CA219187-06 |
| Project ID | NIH-10545765 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with ovarian cancer who have experienced recurrence after initial treatment.
✕Less likely to help
Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates how targeting the Hedgehog signaling pathway can help overcome the challenges of chemoresistance and recurrence in ovarian cancer. The study focuses on understanding the molecular mechanisms that allow ovarian cancer cells to survive and resist treatment, particularly after initial therapies have failed. By inhibiting specific proteins involved in this pathway, the researchers aim to enhance the effectiveness of existing treatments and potentially develop new therapeutic strategies. Patients may benefit from insights that could lead to more effective treatment options for recurrent ovarian cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with recurrent ovarian cancer, potentially increasing survival rates.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in other cancers, suggesting potential for success in this approach for ovarian cancer.
Where this research is happening
-
Texas Tech University Health Scis Center
Lubbock, United States Active
Researchers
- Principal investigator: Palle, Komaraiah — Texas Tech University Health Scis Center
- Study coordinator: Palle, Komaraiah
Related research
Other NIH-funded projects on the same topics.
-
Why prostate cancer spreads more often in African-American men
Looking at whether a gene called FGFR3 and the cell energy systems (OXPHOS) help explain why prostate cancer spreads more in African-American men.
-
Understanding what causes ovarian cancer to come back after treatment
This study is looking at what causes ovarian cancer to come back after treatment, focusing on the genes and other markers that might help predict this, so that women with ovarian cancer can get better, more personalized care in the future.
-
Vaccine to help prevent ovarian cancer from coming back
This vaccine trains Th17 immune cells to help women in first remission from high-grade ovarian cancer stay cancer-free after surgery and chemotherapy.
-
Improving early detection of ovarian cancer recurrence using MUC16 analysis
This study is working on a new way to detect if high-grade serous ovarian cancer comes back by looking at a specific protein in the blood, which could help doctors catch it earlier and manage treatment better for women facing this condition.
-
Keloid recurrence study using multi-omics in diverse patients
A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.